Activation of coagulation in patients with cancer including malignant lymphoma has been observed in earlier reports, namely increased prothrombin activation, elevation of coagulation factor VIII (F VIII) and impairment of platelet function (Zurborn et al, 1986; Nagy and Losonczy, 1987; Nand et al, 1987; Falanga et al, 1994). Here, F2 is linked to lymphoma.